Excellus BCBS · Heart Disease Risk Reduction

Excellus BCBS coverage for Wegovy (Heart Disease Risk Reduction)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 27 or higher
BMI of 25 or higher for patients of Asian descent
Prescribed by or in consultation with a specialist
Established cardiovascular disease (prior_MI, prior_stroke, symptomatic_PAD_with_ABI_less_than_0.85, prior_peripheral_arterial_revascularization, and amputation_due_to_atherosclerotic_disease)
On guideline-directed medical therapy (lipid_lowering_therapy, blood_pressure_lowering_therapy, SGLT2i, and antiplatelet_therapy)
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease without diabetes

All of:

Age ≥ 18 years
BMI ≥ 27 kg/m²
Wegovy prescribed by or in consultation with a cardiologist or neurologist (prescriber attestation required)
Established cardiovascular disease (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease) documented via progress notes
Currently a non-smoker (not smoked in past 6 months)
Partaking in a heart healthy diet
Engaging in physical activity at level of ability
Commitment to continue lifestyle modifications while on Wegovy
Optimized on standard of care treatment for prevention of secondary cardiovascular events per prescriber (may include lipid-lowering, blood pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
No diagnosis of diabetes mellitus
No diagnosis of end-stage renal disease
No NYHA Class IV heart failure symptoms
Not used in combination with any other GIP and/or GLP-1 receptor agonist
Not used in combination with any weight loss drugs (Rx, OTC, or herbal)

Documentation to bring

Baseline BMI documentation (≥27 kg/m²)
Progress notes demonstrating established CVD (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease)
Prescriber attestation that Wegovy is prescribed by or in consultation with a cardiologist or neurologist
Documentation that patient is currently a non-smoker (not smoked in past 6 months)
Documentation that patient is partaking in a heart healthy diet
Documentation that patient is engaging in physical activity at their level of ability
Documentation of patient commitment to continue lifestyle modifications while on Wegovy
Documentation that patient is optimized on standard of care for secondary CVD prevention (lipid-lowering, blood-pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
Documentation that patient has no diagnosis of diabetes mellitus, ESRD, or NYHA Class IV heart failure
At recertification: documentation of ≥80% PDC since last approval
At recertification: documentation of continued non-smoker status, heart-healthy diet, and physical activity

Quantity limits

0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg — 4 pens per 28 days (Wegovy HD 7.2mg NOT approved for CV risk reduction indication); Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days (84-day)
1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days (84-day)

Approval and renewal

Initial approval: 7 months
Renewal: every 6 months
To renew, the plan looks for Upon recertification: patient must be utilizing 2.4mg OR 1.7mg injection OR 25mg tablet as maintenance dose; must demonstrate ≥80% PDC (Percent Days Covered) since last approval; must still be a non-smoker, partaking in a heart healthy diet and engaging in physical activity; must not have developed type 2 diabetes, ESRD, or NYHA Class IV heart failure symptoms. Note: GDMT optimization and CVD diagnosis are not explicitly re-verified at continuation per policy text, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 1.7 mg.

Not covered when

Diabetes mellitus diagnosis excludes from this indication (consider GLP-1 agonists FDA-approved for CV risk reduction in T2DM instead)
End-stage renal disease diagnosis excludes from this indication
NYHA Class IV heart failure symptoms exclude from this indication
Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
Combination with any weight loss drugs (Rx, OTC, or herbal) not approved
Wegovy HD 7.2mg not approved for this indication

Exceptions

New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: Standards of care for secondary CVD prevention may include lipid-lowering therapies, blood pressure-lowering therapy, SGLT2 inhibitors when appropriate, and antiplatelet therapy when appropriate — prescriber determines optimization. Wegovy HD 7.2mg explicitly NOT approved for this indication. For patients with type 2 diabetes seeking CV risk reduction, policy directs to GLP-1 agonists FDA-approved for MACE reduction in T2DM. BMI thresholds may be adjusted for Asian population (≥25 kg/m² suggests clinical obesity) on case-by-case basis. Annual GLP-1 day-supply limits apply cumulatively across all products.

verified June 5, 2026 · source: weight-management-policy-pdf

ACA Marketplace